Cohesive Technologies Inc. Announces Development, Sales, and Support Agreement with Applied Biosystems

FRANKLIN, Mass. — Cohesive Technologies Inc.

(, developers of TurboFlow(R), a technology for high

throughput liquid chromatography systems, announced today that it has entered

into a development, sales, and support agreement with Applied Biosystems Group

(NYSE: ABI), an Applera Corporation business. The agreement covers LC/MS/MS

systems jointly developed by Applied Biosystems and MDS Inc. (Toronto: MDS,

NYSE: MDZ), through its Applied Biosystems/MDS Sciex instrument partnership, a

supplier of mass spectrometers and other analytical instrumentation.

Because the companies have complementary products and technologies, this

agreement allows Cohesive and Applied Biosystems to jointly provide their

customers with a complete, seamless, integrated, high throughput system for

bioanalysis in drug development. Cohesive’s patented chromatography systems,

offering increased productivity and throughput, sample prep elimination, and

high sensitivity, will be integrated with the Applied Biosystems/MDS Sciex

product line of highly sensitive mass spectrometers.

Under this agreement, Cohesive Technologies and Applied Biosystems agree

to broaden their collaboration on joint system development, including

modifying software to provide seamless management and single point control of

all system functions, and developing new applications for the combined


“Our industry leading technology and recently expanded strategic

collaboration with Applied Biosystems enables us to build on our combined

strength in bioanalysis, and provides an opportunity to integrate liquid

chromatography/mass spectrometry systems closer than ever before for our

customers,” said Peter H. Glick, President and CEO of Cohesive Technologies.

“We look forward to continuing our strong collaboration with Applied

Biosystems to maximize the significant opportunities that our companies’

technologies present.”

Cohesive Technologies develops, manufactures, and markets novel liquid

chromatography systems and chemistries for the pharmaceutical and

biotechnology marketplace. Cohesive’s high throughput liquid chromatography

systems have been shown to dramatically increase speed and reduce costs of

bioanalytical testing for drug discovery and development. Researchers at

dozens of major pharmaceutical and biotechnology companies have published

results indicating up to a four-fold increase in sample throughput using

Cohesive’s multiplexing and patented TurboFlow(R) technologies. The Company

has over 300 systems installed worldwide.


< | >